Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4%

Regeneron reported Q3 adjusted EPS of $20.07 versus $16.06 expected and revenue of $5.12 billion versus $4.54 billion expected; revenue rose 36% year over year, and shares gained 4% in premarket trading. Sanofi-related revenue rose 68% to $2.72 billion, driven mainly by Dupixent, while U.S. Eylea sales fell 41% to $400 million; combined U.S. Eylea and Eylea HD sales declined 1% to $1.10 billion. Regeneron raised its 2026 adjusted R&D expense forecast to $6.05 billion-$6.15 billion, lowered its SG&A forecast to $2.4 billion-$2.5 billion, and increased its expected adjusted product gross margin to about 86% from 84%-85%.

Analysis

REGN’s beat is less durable than the headline suggests: it combines strong Dupixent economics with a completed development-balance deduction that lifted recognized partner revenue. The separately announced $1.0B upfront payment should further support Q4, but it is not a recurring sales run rate; milestone revenue is contingent. Strip these effects out before extrapolating EPS. The key operating test is whether Dupixent growth can offset Eylea franchise pressure without relying on Eylea HD price concessions. Flat combined U.S. Eylea/Eylea HD sales imply migration is currently defending the franchise, not yet expanding it. Continued share loss to alternatives such as Roche’s Vabysmo, or further net-price erosion, would make the replacement thesis fail.

Near term, the cemdisiran FDA decision is a binary catalyst next month; approval could add pipeline value, while delay or rejection would expose how much optimism is embedded in the recent move. Over 1–3 months, separate recurring product demand from partnership accounting and the upfront payment. Over 6–18 months, higher R&D investment raises the bar for pipeline productivity; improved gross margin and lower SG&A guidance partly cushion, but do not eliminate, that risk. The contrarian point: investors may over-credit the quarter’s EPS beat while underweighting Eylea’s competitive and pricing risk. Conversely, treating Eylea decline as a near-term earnings cliff may be premature if HD migration sustains combined revenue.

Key Decisions for Investors

• Do not chase the premarket reaction on the headline beat. Reassess after the call or next filing clarifies recurring Dupixent contribution versus the balance-related accounting benefit and Q4 upfront revenue.
• Watch REGN’s next report for combined Eylea/Eylea HD sales, net pricing, and volumes. A renewed decline in combined sales or worsening price concessions would falsify the franchise-stabilization thesis; sustained growth would improve the risk/reward.
• Treat cemdisiran as a defined event risk, not a forecastable earnings contribution: keep exposure modest into the FDA decision and revisit only after the decision and commercial outlook are clear.
• For SNY, avoid inferring a matching earnings upside from REGN’s partner-revenue growth alone; verify Sanofi’s own product economics and guidance before expressing a relative-value view.